Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular and superficial) of high risk and/or locally advanced basal cell carcinoma, in an open label prospective case series clinical trial
Fosko, Scott W., Chu, Melinda B., Armbrecht, Eric, Galperin, Tim, Potts, Geoffrey A., Mattox, Adam, Kurta, Anastasia, Polito, Kristen, Slutsky, Jordan B., Burkemper, Nicole M., Hurley, M YadiraJournal:
Journal of the American Academy of Dermatology
DOI:
10.1016/j.jaad.2019.12.002
Date:
December, 2019
File:
PDF, 1.64 MB
2019
File converter
More search results
More benefits 
